{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lapatinib+%28GW572016%29+1000+mg", "query": { "intervention": "lapatinib (GW572016) 1000 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lapatinib+%28GW572016%29+1000+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T13:47:23.054Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00272987", "title": "ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2005-12-13", "completion_date": "2019-10-21", "has_results": true, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 14, "location_summary": "Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more", "locations": [ { "city": "Roswell", "state": "Georgia" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Voorhees Township", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00272987" }, { "nct_id": "NCT00524303", "title": "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FEC75", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2007-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 23, "location_summary": "Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hudson", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524303" }, { "nct_id": "NCT00804310", "title": "Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2009-08", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2012-03-28", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00804310" }, { "nct_id": "NCT00632489", "title": "LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "LBH589", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2008-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00632489" }, { "nct_id": "NCT00439179", "title": "A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "cohort 1", "type": "DRUG" }, { "name": "cohort 2", "type": "DRUG" }, { "name": "cohort 3", "type": "DRUG" }, { "name": "cohort 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2006-07", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439179" }, { "nct_id": "NCT01087983", "title": "Lapatinib With Sirolimus or Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 111, "start_date": "2010-03", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087983" }, { "nct_id": "NCT00795678", "title": "Chemotherapeutic Agents in Brain/Breast", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2008-09", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 2, "location_summary": "New York, New York • Cleveland, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795678" }, { "nct_id": "NCT00359190", "title": "Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2004-06-29", "completion_date": "2008-01-09", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 8, "location_summary": "Miami, Florida • Durham, North Carolina • Allentown, Pennsylvania + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Allentown", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00359190" }, { "nct_id": "NCT00634088", "title": "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg", "type": "DRUG" }, { "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg", "type": "DRUG" }, { "name": "Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg", "type": "DRUG" }, { "name": "Ixabepilone + Lapatinib + Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2008-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634088" }, { "nct_id": "NCT02213042", "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Aromatase Inhibitors (AIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2014-10-24", "completion_date": "2020-06-04", "has_results": true, "last_update_posted_date": "2021-10-13", "last_synced_at": "2026-10-04T13:47:23.054Z", "location_count": 3, "location_summary": "Mobile, Alabama • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213042" } ] }